Business
Theralase Demonstrates 24 Months Stability of Second Clinical Batch of Lead Anti-Cancer Drug
Theralase Demonstrates 24 Months Stability of Second Clinical Batch of Lead Anti-...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Demonstrates 24 Months Stability of Second Clinical Batch of Lead Anti-Cancer Drug \n\t\t\tbody { font-size: 11pt;\n\t\t\t}\n\n\t\t\t.nr-sub-head ul,\n\t\t\t.nr-body ul {\n\t\t\t\tlist-style-type: disc !important;\n\t\t\t\tmargin-left: 2em !important;\n\t\t\t}\n\n\t\t\t.nr-sub-head ol,\n\t\t\t.nr-body ol {\n\t\t\t\tmargin-left: 2em !important;\n\t\t\t}\n\n\t\t\t.nr-body p, .nr-body {margin-bottom: 0px !important;\n\t\t\t\t\tmargin-top: 0px !important;\n\t\t\t\t\t-webkit-margin-before: 0px !important;\n\t\t\t\t\t-webkit-margin-after: 0px !important;\n\t\t\t\t\tfont-family: Arial !important;\n\t\t\t\t\tfont-size: 11pt !important;\n\t\t\t }\n\n\t\t\ttbody {\n\t\t\t\tborder-top: 0;\n\t\t\t}\n\n\t\t\t H1 {font-weight: bold;\n\t\t\t\tfont-size: 16pt;\n\t\t\t }\n\n\t\t\t H2 {font-weight: bold;\n\t\t\t\tfont-size: 12pt;\n\t\t\t }\n\n\t\t\t H3 {font-weight: bold;\n\t\t\t\tfont-size: 11pt;\n\t\t\t }\n\n\n\t\t\t H1.nr-head {\n\t\t\t \t\tfont-family: Trebuchet MS !important;\n\t\t\t \t\tfont-size: 16pt !important;\n\t\t\t \t\tcolor: #3D86C6 !important;\n\t\t\t \t\tfont-weight:bold !important;\n\t\t\t \t\ttext-align:center !important;\n\n\t\t\t }\n\n\t\t\t H2.nr-sub-head {font-weight: bold !important;\n\t\t\t \t\tdisplay: block !important;\n\t\t\t \t\ttext-align: start !important;\n\t\t\t \t\tfont-family: Arial !important;\n\t\t\t\t\tfont-size: 12pt !important;\n\t\t\t }\n\n\t\t\t .nr-body a { font-size: 11pt !important;\n\t\t\t }\n\n\t\t\t TABLE { width: auto!important;\n\t\t\t }\n\n\t\t Theralase Demonstrates 24 Months Stability of Second Clinical Batch of Lead Anti-Cancer Drug\n Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has demonstrated 24 months long term stability of a second clinical batch of its lead anti-cancer PDC, TLD-1433.\n\n \n\nThe confirmation of 24 months long term stability of the second clinical batch of TLD-1433 ensures that sufficient amount of the PDC will be available at Good Manufacturing Practice (“GMP”) levels for multiple Photo Dynamic Therapy (“PDT”) patient tre...